Peptides with skin condition improving activity and their uses

Abstract

The present application relates to a peptide having skin condition-improving activity and its uses, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1, and a cosmetic composition for improving skin condition that contains the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Description

Technical Field

[0001] This application relates to a peptide having skin condition improving activity and its use.

Background Art

[0002] Human skin is constantly undergoing changes, among which the most typical ones are the decline in skin functions due to aging and the decrease in visual beauty. Aging causes the formation of wrinkles on the skin, and typical factors for wrinkle formation include ultraviolet exposure and reduced biosynthesis of collagen. Skin aging is roughly classified into endogenous aging due to genetic factors and exogenous aging due to external environmental factors such as sunlight. In the case of exogenous aging, it is known that aging can be prevented, treated or delayed through antioxidant removal, promotion of fibroblast proliferation and collagen biosynthesis.

[0003] On the other hand, collagen, which is a major component of the extracellular matrix, is the main matrix protein produced by skin fibroblasts. Collagen forms most of the organic substances in the skin, tendon, bone and teeth, and in particular, its content is high in bone and skin (dermis). Such collagen decreases due to aging caused by age and photoaging due to ultraviolet irradiation, which is known to be closely related to the formation of skin wrinkles. In addition, collagen plays an important role in wound healing and can promote the synthesis of collagen in damaged epithelium to quickly and scarlessly recover the wound. At the same time, it has been reported that when the biosynthesis of collagen is promoted and the density of the basal layer and the like becomes higher, the concentration of melanin pigment per unit skin density becomes lower, and the effect of brightening the skin tone can be expected.

[0004] Under such a technical background, extensive research has been carried out to improve the skin condition through mechanisms such as promoting collagen biosynthesis, enhancing the proliferation and activity of fibroblasts, etc. (Korean Registered Patent No. 10-1813629), but the current situation is still imperfect.

Summary of the Invention

[0005] One embodiment is to provide a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0006] Another embodiment provides a cosmetic composition for improving skin condition that contains a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0007] Other purposes and advantages of this application will be further clarified by the following detailed description, along with the claims and drawings. Any matters not described herein are readily apparent and inferable to those skilled in the art of this application or similar art, and are therefore omitted from this description. [Means for solving the problem]

[0008] Each description and embodiment disclosed in this application may also apply to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not considered to be limited by the specific descriptions described below.

[0009] One embodiment provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0010] As used herein, the term "peptide" may mean a linear molecule formed by the linking of amino acid residues by peptide bonds. Such peptides can be produced by chemical synthesis methods known to those skilled in the art, particularly by solid-phase or liquid-phase synthesis techniques (US Patent No. 5,516,891). The inventors, through diligent efforts to develop a peptide with biologically effective activity, have identified a peptide consisting of the amino acid sequence of Sequence ID No. 1. Here, the biologically effective activity also exhibits one or more properties selected from those such as (a) promotion of fibroblast and keratinocyte proliferation; (b) enhancement of the expression of extracellular matrix components such as collagen type 1 (Col1a1), fibronectin, or elastin; and (c) enhancement of the expression of skin barrier factors such as sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3). Therefore, such peptides can be utilized for skin condition improvement or antioxidant applications.

[0011] The peptides may also have a protecting group attached to the N-terminus or C-terminus to acquire chemical stability, enhanced pharmacological properties (half-life, water absorption, potency, efficacy, etc.), altered specificity (e.g., broad biological activity spectrum), or reduced antigenicity. In one specific example, the N-terminus of the peptide is bonded to one protecting group selected from the group consisting of acetyl, fluorenylmethoxycarbonyl, formyl, palmitoyl, myristyl, stearyl, butoxycarbonyl, allyloxycarbonyl, and polyethylene glycol (PEG); and / or, the C-terminus of the peptide may be bonded to one protecting group selected from the group consisting of amino, -NH2, tertiary alkyl, and azide (-NHNH2). The peptide may also selectively further include a targeted sequence, a tag, labeled residues, or an amino acid sequence manufactured for a specific purpose to increase half-life or peptide stability.

[0012] As used herein, the term "stability" may refer not only to in vivo stability, which protects the peptide from attack by endogenous protein-cleaving enzymes, but also to storage stability (e.g., room temperature storage stability).

[0013] Another embodiment provides a cosmetic composition for improving skin condition that contains a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0014] As stated above, any terms or elements mentioned in the description of the peptides that are the same as those already mentioned are as described above.

[0015] As used herein, the term "improvement" may mean any action that alleviates or treats a condition, such as any action that at least reduces the severity of the symptoms.

[0016] As used herein, the term "improvement of skin condition" comprehensively refers to the process or effect of treating, reducing, or mitigating skin damage induced by intrinsic or extrinsic factors of the skin, and may, but is not limited to, wrinkle reduction, improved skin elasticity, wound healing, strengthening of the skin barrier, or inhibition of skin aging.

[0017] Here, "wrinkle improvement," "skin elasticity improvement," and "wound healing" can refer to all effects that increase the total amount of extracellular matrix factors, including the promotion of collagen synthesis. Furthermore, "strengthening the skin barrier" can refer to enhancing the skin's natural functions, such as preventing leakage of moisture and nutrients from the skin and preventing the penetration of harmful substances like bacteria and viruses into the skin. Additionally, "suppression of skin aging" can refer to suppressing the decline of skin function, such as wrinkles, sagging, and loss of elasticity. In this context, the aforementioned skin aging also includes photoaging, such as skin aging caused by ultraviolet radiation.

[0018] Conventional functional peptides, despite their effective biological activity, suffer from disadvantages such as not being effectively absorbed into target tissues or cells due to their size, or being eliminated from the body quickly due to their short half-life. On the other hand, the cosmetic composition according to one example contains a peptide consisting of 10 or fewer amino acids as an active ingredient, resulting in excellent skin penetration of the active ingredient. For example, when applied topically to the skin, it can effectively improve skin condition.

[0019] According to one embodiment, the proliferation of fibroblasts and keratinocytes was promoted, and the synthesis of extracellular matrix components and skin barrier factors was improved. Therefore, the peptide can be used as an active ingredient in cosmetic compositions for improving skin condition.

[0020] The cosmetic composition may also contain, but is not limited to, a cosmetically effective amount of the peptide and / or a cosmetically acceptable carrier.

[0021] As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the skin condition improving efficacy of the cosmetic composition.

[0022] The weight ratio between the peptide and the cosmetically acceptable carrier may be, for example, 500:1 to 1:500, and may also be, but is not limited to, 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2.

[0023] The aforementioned cosmetic composition may be manufactured in any dosage form commonly produced in the industry, such as, but is not limited to, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, and sprays. For example, it may also be manufactured in the form of softening lotions, nourishing lotions, nourishing creams, massage creams, essences, eye creams, cleansing creams, cleansing foams, cleansing waters, packs, sprays, or powders.

[0024] When the dosage form of the cosmetic composition is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, tragacanths, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talcs or zinc oxides can be used as carrier components.

[0025] When the dosage form of the cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder is used as a carrier component. For example, in the case of a spray, it can further contain a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether.

[0026] When the dosage form of the cosmetic composition is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component. For example, it can contain water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty acid ester, polyethylene glycol or sorbitan fatty acid ester.

[0027] When the dosage form of the cosmetic composition is a suspension, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth can be used as carrier components.

[0028] When the dosage form of the cosmetic composition is a surfactant-containing cleanser, the carrier component may be an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinate monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

[0029] The peptide may be contained in nanosomes or nanoparticles to further improve skin penetration or stability issues. For example, the nanosomes may be produced by a microfluidizer using lecithin as a raw material and contained within lecithin particles. Any known method for producing the nanosomes may be used. The size of the nanosome particles is preferably 30 to 200 nm. If the size of the nanosome particles is less than 30 nm, skin penetration proceeds very quickly, causing skin side effects, and if it exceeds 200 nm, skin penetration is not easy, making it difficult to obtain the benefits of using the nanosome structure.

[0030] In addition to the peptide and carrier components as active ingredients, the components contained in the cosmetic composition may include ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0031] The content of peptides as active ingredients in the cosmetic composition can be appropriately and non-restrictively selected depending on the product form, desired use, etc., and can be added in amounts of, for example, 0.01 to 15% by weight of the total weight of the cosmetic composition. Alternatively, for example, the cosmetic composition may contain peptides in amounts of 1.0% to 3.0% by weight, preferably 2.0% to 3.0% by weight, based on the total weight.

[0032] Further embodiments include a method for improving skin condition, comprising the step of applying a cosmetic composition containing a peptide comprising the amino acid sequence of SEQ ID NO: 1 as an active ingredient to the skin of an individual; and providing uses for the peptide comprising the amino acid sequence of SEQ ID NO: 1 for the production of compositions for improving skin condition.

[0033] As stated above, any terms or elements mentioned in the description relating to the cosmetic composition that are the same as those already mentioned are as described above.

[0034] As used herein, the term “individual” means an individual subject requiring improvement of skin condition, and more specifically, a mammal such as a human or non-human primate, mouse, dog, cat, horse, and cattle.

[0035] As used herein, the terms “apply,” “administer,” and “coat” are interchangeable and may mean bringing the composition according to one embodiment to a desired site at least partially, or placing the composition according to one embodiment within an individual via an administration route.

[0036] Another embodiment provides an antioxidant composition containing a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0037] As stated above, any terms or elements mentioned in the description of the peptides that are the same as those already mentioned are as described above.

[0038] The antioxidant composition may also be in the form of a pharmaceutical composition, a quasi-drug composition, or a cosmetic composition. For example, the composition may be used as a cosmetic composition for improving skin condition, or as a pharmaceutical composition for improving or treating the condition of diseases related to skin damage.

[0039] According to one embodiment, the peptide can restore the inhibited activity of fibroblasts and keratinocytes, thereby improving their antioxidant activity. Therefore, the peptide can be used as an active ingredient in antioxidant compositions.

[0040] The antioxidant composition may, for example, be provided in the form of a pharmaceutically effective composition. The pharmaceutically effective composition may also contain, but is not limited to, a pharmaceutically effective amount of the peptide and / or a pharmaceutically acceptable carrier.

[0041] As used herein, the term "pharmaceutical effective amount" may mean an amount sufficient to achieve the preventive or therapeutic efficacy of the pharmaceutical composition for diseases related to skin damage.

[0042] The pharmaceutically acceptable carriers mentioned above are those commonly used in formulation and include, but are not limited to, lactose, dextrose, saccharose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoic acid, propylhydroxybenzoic acid, talc, magnesium stearate, and mineral oil. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0043] The weight ratio between the peptide and the pharmaceutically acceptable carrier may be, for example, 500:1 to 1:500, and may also be, but is not limited to, 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2.

[0044] The aforementioned pharmaceutical composition may further contain, but is not limited to, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspension agents, preservatives, and the like, in addition to the aforementioned components.

[0045] The aforementioned pharmaceutical composition may be administered orally or parenterally, preferably parenterally, and in the case of parenteral administration, it may be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, local administration, transdermal administration, etc., but is not limited to these.

[0046] The dosage of the aforementioned pharmaceutical composition may be 0.0001 to 1000 μg (micrograms), 0.001 to 1000 μg, 0.01 to 1000 μg, 0.1 to 1000 μg, or 1.0 to 1000 μg per day, but is not limited to these values ​​and can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, medical condition, diet, administration time, route of administration, excretion rate, and response sensitivity.

[0047] The pharmaceutical composition may be manufactured in unit dose form or encapsulated in a multi-dose container by formulating it with pharmaceutically acceptable carriers and / or excipients using a method readily available to a person with ordinary skill in the art to which the invention pertains.

[0048] The dosage form may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablet or capsule, and may additionally contain a dispersant and / or stabilizer.

[0049] Another embodiment provides a food composition for improving skin condition that contains a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0050] As stated above, any terms or elements mentioned in the description of the peptides that are the same as those already mentioned are as described above.

[0051] The content of the peptide as an active ingredient contained in the food composition can be appropriately and non-restrictively selected depending on the form of the food, the desired use, etc., and can be added in an amount of 0.01 to 15% by weight of the total food weight. Also, for example, in a health beverage composition, it can be added in a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml. [Effects of the Invention]

[0052] According to one embodiment of the peptide, by promoting the proliferation of fibroblasts and keratinocytes and improving the synthesis of extracellular matrix components and skin barrier factors, it can be applied to improve skin conditions, including wrinkle reduction, improved skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging.

[0053] Therefore, a peptide according to one embodiment can be used as an active ingredient in a composition for improving skin condition. [Brief explanation of the drawing]

[0054] [Figure 1] The peptide consisting of the amino acid sequence of Sequence ID No. 1 was added to skin cells, and the cell proliferation level was checked. Figure 1A shows the result of the change in viability of NIH3T3 cells, and Figure 1B shows the result of the change in viability of HaCaT cells. [Figure 2]This study shows the results of adding a peptide consisting of the amino acid sequence of Sequence ID No. 1 to NIH3T3 cells, followed by an increase in the expression of extracellular matrix components Col1a1, fibronectin, and elastin. [Figure 3] The expression levels of extracellular matrix components were quantitatively evaluated after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. Figure 3A shows the results of confirming the expression level of Col1a1, Figure 3B shows the results of confirming the expression level of fibronectin, and Figure 3C shows the results of confirming the expression level of elastin. [Figure 4] This result shows that after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells, an increase in the expression of SIRT-1 and AQP3, which are skin barrier factors, was confirmed. [Figure 5] The expression levels of skin barrier factors were quantitatively evaluated after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. Figure 5A shows the results of confirming the expression level of SIRT-1, and Figure 5B shows the results of confirming the expression level of AQP3. [Figure 6] This is the result of quantitatively confirming the change in reactive oxygen species levels, which were increased by ultraviolet light, after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells. [Figure 7] This is the result of quantitatively confirming the change in reactive oxygen species levels, which were increased by ultraviolet light, after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells. [Modes for carrying out the invention]

[0055] The present invention will be described in more detail below based on examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.

[0056] Example 1. Synthesis of peptides Peptides having the amino acid sequence of SEQ ID NO: 1, as shown in [Table 1] below, were synthesized using an automated peptide synthesizer (Milligen 9050, Millipore, USA), and these synthesized peptides were separated into pure molecules using C18 reversed-phase high-performance liquid chromatography (HPLC) (Waters Associates, USA). The column used was ACQUITY UPLC BEH300C18 (2.1 mm x 100 mm, 1.7 μm, Waters Co., USA).

[0057] [Table 1]

[0058] Example 2. Confirmation of the proliferation-promoting effect on skin cells In this example, the effect of the peptide from one example on skin cell proliferation was confirmed by evaluating the changes in the viability of mouse fibroblasts (NIH3T3 cells) or human keratinocytes (HaCaT cells).

[0059] Specifically, NIH3T3 cells or HaCaT cells are placed in a 96-well plate in a 5 × 10⁶ 3 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 200 μL of the serum-free media. This was then cultured in a CO2 incubator at 37°C for 72 hours. Subsequently, the cultures were washed twice with PBS, and then 0.5 mg / ml of MTT (Sigma, Cat. No.: M2003, USA) solution was dispensed into each well. After being shielded from light, the cultures were cultured in a CO2 incubator at 37°C for 4 hours. Absorbance at 540 nm was then measured. In this example, the control group was the untreated group, and the positive control group was the group supplemented with insulin-like growth factor (IGF).

[0060] As a result, as shown in Figure 1, we confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 promotes the proliferation of fibroblasts and keratinocytes.

[0061] Example 3. Confirmation of wrinkle improvement and elasticity enhancement effects. In this example, the effects of the peptide from this example on improving intrinsic skin aging, including wrinkle reduction and increased elasticity, were confirmed by evaluating the expression levels of collagen type 1 (Col1a1), fibronectin, or elastin, which are known components of the dermis.

[0062] Specifically, NIH3T3 cells were placed in a 6-well plate in a 3 x 10⁶ arrangement. 5 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and then 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the culture medium and cultured in a CO2 incubator at 37°C for 24 hours. Subsequently, the culture was washed twice with PBS, and RNA was isolated from the culture using easy blue (iNtRON, Korea). Using RT kit (Enzynomics, Korea), 1 μg of the isolated RNA was reverse transcribed to synthesize the respective cDNAs. Subsequently, polymerase chain reaction (PCR) was performed using the cDNAs, Col1a1, fibronectin, and elastin primers. The control group was the untreated group, and the positive control group was the group supplemented with TGF-β1 (TGF-β1). The nucleotide sequences of the primers used in this example are shown in Table 2 below.

[0063] [Table 2]

[0064] As a result, as shown in Figures 2 and 3, it was confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 increased the expression of extracellular matrix components Col1a1, fibronectin, and elastin. Through these results, it was found that the peptide according to one example contributes to the improvement of intrinsic skin aging, including wrinkle reduction and increased elasticity, by increasing extracellular matrix components.

[0065] Example 4. Confirmation of the effect of strengthening the skin barrier. In this example, the effect of the peptide from this example on strengthening the skin barrier was confirmed by evaluating the expression levels of sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3).

[0066] Specifically, HaCaT cells were placed in a 6-well plate in a 3 x 10⁶ arrangement. 5 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and then 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the culture medium and cultured in a CO2 incubator at 37°C for 24 hours. Subsequently, the culture was washed twice with PBS, and RNA was isolated from the culture using easy blue (iNtRON, Korea). Using RT kit (Enzynomics, Korea), 1 μg of the isolated RNA was reverse transcribed to synthesize the respective cDNAs. Subsequently, polymerization enzyme chain reactions were carried out using the cDNAs, sirtuin-1, and aquaforin-3 primers. The control group was the untreated group, and the positive control group was the group supplemented with EGF (EGF). The nucleotide sequences of the primers used in this example are shown in Table 3 below.

[0067] [Table 3]

[0068] As a result, as shown in Figures 4 and 5, it was confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 increased the expression of SIRT-1 and AQP3, which are skin barrier factors. Through these results, it was found that the peptide according to one example contributes to strengthening the skin barrier and anti-aging of the skin by increasing skin barrier factors.

[0069] Example 5. Confirmation of the effect of reducing reactive oxygen species increased by ultraviolet light. In this example, the effect of the peptide according to one example on the antioxidant effect in damaged skin cells was confirmed by evaluating the change in the level of reactive oxygen species in skin cells that increased due to ultraviolet irradiation.

[0070] Specifically, NIH3T3 cells or HaCaT cells are placed in a 6-well plate in a 5 × 10⁶ arrangement. 5 After seeding at a density of cells / well, the cells were cultured for 24 hours. Subsequently, the cells were washed once with serum-free DMEM media, and then 50 μM or 100 μM of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was dispensed into 1 mL of the culture medium. This was then cultured in a CO2 incubator at 37°C for 1 hour. The culture was then transferred to an e-tube, mixed with 1 mL of PBS, and dispensed into well plates. Finally, UV irradiation (VILBER LOURMAT, Cat No.: 3102-BSU, France) was used to target NIH3T3 cells at 8 J / cm². 2Ultraviolet light was irradiated, and HaCaT cells were targeted with 15 mJ / cm2 of ultraviolet light. Subsequently, after removing the PBS from the well plate, 900 μL of culture medium containing the peptide was added, and the cells were incubated in a CO2 incubator at 37°C for 24 hours. Subsequently, the culture was treated with DCFH-DA (2',7'-dichlorofluorescin diacetate), covered with foil, and incubated in a CO2 incubator at 37°C for 30 minutes. After washing twice with PBS, 500 μL of 1× trypsin / EDTA was added to obtain cells, and then centrifugation was performed. After washing the centrifuged cells with PBS, the fluorescence value was measured by flow cytometry (FACS, BD, USA). In this example, the control group was the untreated group, the comparison group (NC) was the group irradiated with ultraviolet light only, and the positive control group was the group to which 50 μM Trolox was added.

[0071] As a result, as shown in Figures 6 and 7, it was confirmed that the peptide consisting of the amino acid sequence of Sequence ID No. 1 reduced the levels of reactive oxygen species in fibroblasts and keratinocytes that were increased by UV irradiation. Through these results, it was found that the peptide according to one example contributes to the antioxidant effect on UV-induced skin cells.

[0072] Dosage Form Example 1: Production of Peptide Nanosomes 50 mg of the peptide from Example 1 was dissolved in 500 ml of distilled water by thorough stirring. The mixture was then mixed with 5 g of lecithin, 0.3 ml of sodium oleate, 50 ml of ethanol, and a small amount of oil. After adjusting the volume with distilled water to a total of 1 L, the mixture was emulsified using a microfluidizer under high pressure to produce peptide nanosomes with a size of approximately 100 nm.

[0073] Dosage form example 2. Softening lotion A softening lotion containing a peptide according to one embodiment and having the following composition was manufactured using a method known in the industry.

[0074] [Table 4]

[0075] Dosage form example 3: Nutritional cream A nutritional cream containing a peptide according to one embodiment and having the following composition was manufactured using a method known in the industry.

[0076] [Table 5]

[0077] Dosage form example 4. Nourishing lotion A nourishing lotion containing a peptide according to one embodiment and having the following composition was manufactured using a method known in the industry.

[0078] [Table 6]

[0079] Dosage Form Example 5: Essence An essence containing a peptide according to one embodiment and having the following composition was prepared using a method known in the industry.

[0080] [Table 7]

[0081] The above description of the present invention is illustrative, and a person with ordinary skill in the art to which the invention pertains will understand that it can be easily modified into other specific forms without altering the technical idea or essential features of the invention. Therefore, the embodiments described above should be understood to be illustrative in all respects and not limiting.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1, wherein the N-terminus of the peptide is bonded to one protecting group selected from the group consisting of an acetyl group, a fluoreonylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and polyethylene glycol (PEG).

3. The C-terminus of the peptide is an amino group (-NH₂). 2 ), tertiary alkyl group and azide (-NHNH) 2 The peptide according to claim 1, which is bonded to any one protecting group selected from the group consisting of ).

4. The peptide according to claim 1, wherein the peptide exhibits one or more of the following characteristics: (a) Promoting the proliferation of fibroblasts or keratinocytes; (b) Enhanced expression of extracellular matrix components such as collagen type 1 (Col1a1), fibronectin, or elastin; (c) Enhanced expression of skin barrier factors, sirtuin-1 (SIRT-1) or aquaforin-3 (AQP3).

5. A cosmetic composition for improving skin condition, comprising the peptide described in any one of claims 1 to 4 as an active ingredient.

6. The cosmetic composition according to claim 5, wherein the peptide is formulated into nanosomes.

7. The cosmetic composition according to claim 5, wherein the improvement of skin condition is wrinkle reduction, improvement of skin elasticity, wound healing, strengthening of the skin barrier, or suppression of skin aging.

8. The cosmetic composition according to claim 7, wherein the skin aging is skin aging caused by ultraviolet light.

Images